Raymond James & Associates
MBRX icon

Raymond James & Associates’s Moleculin Biotech MBRX Stock Holding History

Raymond James & Associates’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2
Closed -$43K – 4227
2021
Q3 		$43K Hold
2
– – ﹤0.01% 3928
2021
Q2 		$55K Hold
2
– – ﹤0.01% 3906
2021
Q1 		$61K Buy
+2
New +$73.3K ﹤0.01% 3837

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sio Capital Management
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Virtu Financial
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Occudo Quantitative Strategies
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.88B AUM 35.68% 1-Year Est. Return

Raymond James & Associates's MBRX Position: Q4 2021 in Review

Raymond James & Associates sold out of Moleculin Biotech (MBRX) in Q4 2021, closing a stake of 2 shares — an estimated $43K sold.

Raymond James & Associates first reported a position in MBRX in Q1 2021 and held it in 3 quarters. The position peaked at $61K in Q1 2021. 18 funds tracked by Wall St. Rank hold MBRX as of Q4 2021.

  • Raymond James & Associates reported no remaining Moleculin Biotech position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 2 Moleculin Biotech shares in Q4 2021, an estimated $43K.
  • Raymond James & Associates first reported a position in Moleculin Biotech in Q1 2021 and held it in 3 quarters.
  • Raymond James & Associates's Moleculin Biotech position peaked at $61K in Q1 2021.
  • 18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.